Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients

Kazuo Chin, Takaya Nakamura, Kenichi Takahashi, Kensuke Sumi, Yoshihiro Ogawa, Hiroaki Masuzaki, Shigeo Muro, Noboru Hattori, Hisako Matsumoto, Akio Niimi, Tsutomu Chiba, Kazuwa Nakao, Michiaki Mishima, Motoharu Ohi, Takashi Nakamura

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

PURPOSE: Obesity has been associated with obstructive sleep apnea and hepatic steatosis. We investigated the effects of obstructive sleep apnea and treatment with nasal continuous positive airway pressure (CPAP) on serum aminotransferase levels in obese patients. METHODS: We studied 40 obese men with obstructive sleep apnea syndrome. None had hepatitis B antigen or C antibody, autoimmune disease, or an excessive intake of alcohol. Serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride, glucose, insulin, and leptin were determined in the afternoon and in the morning immediately after sleep, before and after nasal CPAP treatment. RESULTS: Aminotransferase levels were abnormal in 35% (n = 14) of patients. Before treatment, mean (± SD) aspartate aminotransferase levels were higher in the morning than in the previous afternoon (presleep, 34 ± 20 IU/L; postsleep, 39 ± 28 IU/L; P = 0.006). The overnight mean increases in aminotransferase levels were less marked after the first night of nasal CPAP treatment (aspartate aminotransferase: from 6 ± 11 IU/L to 2 ± 6 IU/L, P = 0.0003; alanine aminotransferase: from 5 ± 9 IU/L to 2 ± 6 IU/L, P = 0.006). Leptin levels (n = 23) decreased significantly after treatment (P = 0.0002), whereas insulin resistance (calculated by the homeostasis model assessment method) and triglyceride levels were unchanged. Improvements in aspartate and alanine aminotransferase levels were maintained after 1 and 6 months of nasal CPAP treatment. CONCLUSION: Nasal CPAP therapy may have beneficial effects on serum aminotransferase abnormalities in obese patients who have obstructive sleep apnea.

Original languageEnglish
Pages (from-to)370-376
Number of pages7
JournalAmerican Journal of Medicine
Volume114
Issue number5
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Obstructive Sleep Apnea
Transaminases
Continuous Positive Airway Pressure
Aspartate Aminotransferases
Serum
Alanine Transaminase
Leptin
Therapeutics
Triglycerides
Hepatitis B Antigens
Hepatitis B Antibodies
Hepatitis C Antibodies
Autoimmune Diseases
Insulin Resistance
Sleep
Homeostasis
Obesity
Alcohols
Insulin
Glucose

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. / Chin, Kazuo; Nakamura, Takaya; Takahashi, Kenichi; Sumi, Kensuke; Ogawa, Yoshihiro; Masuzaki, Hiroaki; Muro, Shigeo; Hattori, Noboru; Matsumoto, Hisako; Niimi, Akio; Chiba, Tsutomu; Nakao, Kazuwa; Mishima, Michiaki; Ohi, Motoharu; Nakamura, Takashi.

In: American Journal of Medicine, Vol. 114, No. 5, 01.04.2003, p. 370-376.

Research output: Contribution to journalArticle

Chin, K, Nakamura, T, Takahashi, K, Sumi, K, Ogawa, Y, Masuzaki, H, Muro, S, Hattori, N, Matsumoto, H, Niimi, A, Chiba, T, Nakao, K, Mishima, M, Ohi, M & Nakamura, T 2003, 'Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients', American Journal of Medicine, vol. 114, no. 5, pp. 370-376. https://doi.org/10.1016/S0002-9343(02)01570-X
Chin, Kazuo ; Nakamura, Takaya ; Takahashi, Kenichi ; Sumi, Kensuke ; Ogawa, Yoshihiro ; Masuzaki, Hiroaki ; Muro, Shigeo ; Hattori, Noboru ; Matsumoto, Hisako ; Niimi, Akio ; Chiba, Tsutomu ; Nakao, Kazuwa ; Mishima, Michiaki ; Ohi, Motoharu ; Nakamura, Takashi. / Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. In: American Journal of Medicine. 2003 ; Vol. 114, No. 5. pp. 370-376.
@article{165c9f5d72cb4917a7c034139ad32168,
title = "Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients",
abstract = "PURPOSE: Obesity has been associated with obstructive sleep apnea and hepatic steatosis. We investigated the effects of obstructive sleep apnea and treatment with nasal continuous positive airway pressure (CPAP) on serum aminotransferase levels in obese patients. METHODS: We studied 40 obese men with obstructive sleep apnea syndrome. None had hepatitis B antigen or C antibody, autoimmune disease, or an excessive intake of alcohol. Serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride, glucose, insulin, and leptin were determined in the afternoon and in the morning immediately after sleep, before and after nasal CPAP treatment. RESULTS: Aminotransferase levels were abnormal in 35{\%} (n = 14) of patients. Before treatment, mean (± SD) aspartate aminotransferase levels were higher in the morning than in the previous afternoon (presleep, 34 ± 20 IU/L; postsleep, 39 ± 28 IU/L; P = 0.006). The overnight mean increases in aminotransferase levels were less marked after the first night of nasal CPAP treatment (aspartate aminotransferase: from 6 ± 11 IU/L to 2 ± 6 IU/L, P = 0.0003; alanine aminotransferase: from 5 ± 9 IU/L to 2 ± 6 IU/L, P = 0.006). Leptin levels (n = 23) decreased significantly after treatment (P = 0.0002), whereas insulin resistance (calculated by the homeostasis model assessment method) and triglyceride levels were unchanged. Improvements in aspartate and alanine aminotransferase levels were maintained after 1 and 6 months of nasal CPAP treatment. CONCLUSION: Nasal CPAP therapy may have beneficial effects on serum aminotransferase abnormalities in obese patients who have obstructive sleep apnea.",
author = "Kazuo Chin and Takaya Nakamura and Kenichi Takahashi and Kensuke Sumi and Yoshihiro Ogawa and Hiroaki Masuzaki and Shigeo Muro and Noboru Hattori and Hisako Matsumoto and Akio Niimi and Tsutomu Chiba and Kazuwa Nakao and Michiaki Mishima and Motoharu Ohi and Takashi Nakamura",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0002-9343(02)01570-X",
language = "English",
volume = "114",
pages = "370--376",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients

AU - Chin, Kazuo

AU - Nakamura, Takaya

AU - Takahashi, Kenichi

AU - Sumi, Kensuke

AU - Ogawa, Yoshihiro

AU - Masuzaki, Hiroaki

AU - Muro, Shigeo

AU - Hattori, Noboru

AU - Matsumoto, Hisako

AU - Niimi, Akio

AU - Chiba, Tsutomu

AU - Nakao, Kazuwa

AU - Mishima, Michiaki

AU - Ohi, Motoharu

AU - Nakamura, Takashi

PY - 2003/4/1

Y1 - 2003/4/1

N2 - PURPOSE: Obesity has been associated with obstructive sleep apnea and hepatic steatosis. We investigated the effects of obstructive sleep apnea and treatment with nasal continuous positive airway pressure (CPAP) on serum aminotransferase levels in obese patients. METHODS: We studied 40 obese men with obstructive sleep apnea syndrome. None had hepatitis B antigen or C antibody, autoimmune disease, or an excessive intake of alcohol. Serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride, glucose, insulin, and leptin were determined in the afternoon and in the morning immediately after sleep, before and after nasal CPAP treatment. RESULTS: Aminotransferase levels were abnormal in 35% (n = 14) of patients. Before treatment, mean (± SD) aspartate aminotransferase levels were higher in the morning than in the previous afternoon (presleep, 34 ± 20 IU/L; postsleep, 39 ± 28 IU/L; P = 0.006). The overnight mean increases in aminotransferase levels were less marked after the first night of nasal CPAP treatment (aspartate aminotransferase: from 6 ± 11 IU/L to 2 ± 6 IU/L, P = 0.0003; alanine aminotransferase: from 5 ± 9 IU/L to 2 ± 6 IU/L, P = 0.006). Leptin levels (n = 23) decreased significantly after treatment (P = 0.0002), whereas insulin resistance (calculated by the homeostasis model assessment method) and triglyceride levels were unchanged. Improvements in aspartate and alanine aminotransferase levels were maintained after 1 and 6 months of nasal CPAP treatment. CONCLUSION: Nasal CPAP therapy may have beneficial effects on serum aminotransferase abnormalities in obese patients who have obstructive sleep apnea.

AB - PURPOSE: Obesity has been associated with obstructive sleep apnea and hepatic steatosis. We investigated the effects of obstructive sleep apnea and treatment with nasal continuous positive airway pressure (CPAP) on serum aminotransferase levels in obese patients. METHODS: We studied 40 obese men with obstructive sleep apnea syndrome. None had hepatitis B antigen or C antibody, autoimmune disease, or an excessive intake of alcohol. Serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride, glucose, insulin, and leptin were determined in the afternoon and in the morning immediately after sleep, before and after nasal CPAP treatment. RESULTS: Aminotransferase levels were abnormal in 35% (n = 14) of patients. Before treatment, mean (± SD) aspartate aminotransferase levels were higher in the morning than in the previous afternoon (presleep, 34 ± 20 IU/L; postsleep, 39 ± 28 IU/L; P = 0.006). The overnight mean increases in aminotransferase levels were less marked after the first night of nasal CPAP treatment (aspartate aminotransferase: from 6 ± 11 IU/L to 2 ± 6 IU/L, P = 0.0003; alanine aminotransferase: from 5 ± 9 IU/L to 2 ± 6 IU/L, P = 0.006). Leptin levels (n = 23) decreased significantly after treatment (P = 0.0002), whereas insulin resistance (calculated by the homeostasis model assessment method) and triglyceride levels were unchanged. Improvements in aspartate and alanine aminotransferase levels were maintained after 1 and 6 months of nasal CPAP treatment. CONCLUSION: Nasal CPAP therapy may have beneficial effects on serum aminotransferase abnormalities in obese patients who have obstructive sleep apnea.

UR - http://www.scopus.com/inward/record.url?scp=0037396722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037396722&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(02)01570-X

DO - 10.1016/S0002-9343(02)01570-X

M3 - Article

C2 - 12714126

AN - SCOPUS:0037396722

VL - 114

SP - 370

EP - 376

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5

ER -